UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The expanding universe of NUTM1 fusions in pediatric cancer

Clinical and translational science, 2023-08, Vol.16 (8), p.1331-1339

2023

Volltextzugriff (PDF)

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

Clinical cancer research, 2017-05, Vol.23 (9), p.2131-2135

2017

Volltextzugriff (PDF)

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer

Clinical cancer research, 2017-12, Vol.23 (23), p.7165-7170

2017

Volltextzugriff (PDF)

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Clinical cancer research, 2021-04, Vol.27 (7), p.1850-1854

2021

Volltextzugriff (PDF)

Purification, Cloning, and Expression of a Novel Salivary Anticomplement Protein from the Tick, Ixodes scapularis

The Journal of biological chemistry, 2000-06, Vol.275 (25), p.18717-18723

2000

Volltextzugriff (PDF)

Toward an Understanding of the Biochemical and Pharmacological Complexity of the Saliva of a Hematophagous Sand Fly Lutzomyia longipalpis

Proceedings of the National Academy of Sciences - PNAS, 1999-12, Vol.96 (26), p.15155-15160

1999

Volltextzugriff (PDF)

Systematic identification of pseudogenes through whole genome expression evidence profiling

Nucleic acids research, 2006-09, Vol.34 (16), p.4477-4485

2006

Volltextzugriff (PDF)

Fine‐Tuning the Relevance of Molecular Targets to Pediatric Cancer: Addressing Additional Layers of Complexity

Clinical pharmacology and therapeutics, 2023-05, Vol.113 (5), p.957-959

2023

Volltextzugriff (PDF)

Assessing Information Gaps Associated with Initial Pediatric Study Plans for New Oncology Drug and Biological Products

Clinical pharmacology and therapeutics, 2023-09, Vol.114 (3), p.618-622

2023

Volltextzugriff (PDF)

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

Clinical cancer research, 2021-02, Vol.27 (4), p.922-927

2021

Volltextzugriff (PDF)

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical cancer research, 2015-11, Vol.21 (21), p.4760-4766

2015

Volltextzugriff (PDF)

Effect of Obesity on the Pharmacokinetics and Pharmacodynamics of Anticancer Agents

Journal of clinical pharmacology, 2023-11, Vol.63 (S2), p.S85-S102

2023

Volltextzugriff (PDF)

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Clinical cancer research, 2019-06, Vol.25 (11), p.3205-3209

2019

Volltextzugriff (PDF)

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

Clinical cancer research, 2021-10, Vol.27 (20), p.5452-5456

2021

Volltextzugriff (PDF)

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Clinical cancer research, 2015-06, Vol.21 (12), p.2666-2670

2015

Volltextzugriff (PDF)

Pediatric Cancer Drug Development: Leveraging Insights in Cancer Biology and the Evolving Regulatory Landscape to Address Challenges and Guide Further Progress

Cold Spring Harbor perspectives in medicine, 2024-04, Vol.14 (4), p.a041656

2024

Volltextzugriff (PDF)

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

Clinical cancer research, 2020-08, Vol.26 (16), p.4280-4288

2020

Volltextzugriff (PDF)

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions

Clinical cancer research, 2021-04, Vol.27 (8), p.2130-2135

2021

Volltextzugriff (PDF)

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors

Clinical cancer research, 2022-11, Vol.28 (22), p.4843-4848

2022

Volltextzugriff (PDF)

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Clinical cancer research, 2023-09, Vol.29 (17), p.3262-3266

2023

Volltextzugriff (PDF)

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Clinical cancer research, 2022-07, Vol.28 (13), p.2733-2737

2022

Volltextzugriff (PDF)

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer

The oncologist (Dayton, Ohio), 2021-02, Vol.26 (2), p.139-146

2021

Volltextzugriff (PDF)

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Clinical cancer research, 2023-03, Vol.29 (5), p.838-842

2023

Volltextzugriff (PDF)

FDA Approval Summary: Capecitabine Labeling Update under Project Renewal

Clinical cancer research, 2024-10

2024

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(56)

Sprache

Englisch
(55)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(48)
Humans
(32)
Oncology
(24)
Animals
(19)
Drug Approval
(15)
Female
(15)
United States
(15)
Adult
(12)
United States Food And Drug Administration
(12)
Mutation
(10)
Psychodidae
(8)
Amino Acid Sequence
(7)
Biochemistry & Molecular Biology
(7)
Lutzomyia Longipalpis
(7)
Molecular Sequence Data
(7)
Pharmacology & Pharmacy
(7)
Salivary Glands
(7)
Biological And Medical Sciences
(6)
Male
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The expanding universe of NUTM1 fusions in pediatric cancer

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Purification, Cloning, and Expression of a Novel Salivary Anticomplement Protein from the Tick, Ixodes scapularis

Toward an Understanding of the Biochemical and Pharmacological Complexity of the Saliva of a Hematophagous Sand Fly Lutzomyia longipalpis

Systematic identification of pseudogenes through whole genome expression evidence profiling

Fine‐Tuning the Relevance of Molecular Targets to Pediatric Cancer: Addressing Additional Layers of Complexity

Assessing Information Gaps Associated with Initial Pediatric Study Plans for New Oncology Drug and Biological Products

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Effect of Obesity on the Pharmacokinetics and Pharmacodynamics of Anticancer Agents

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Pediatric Cancer Drug Development: Leveraging Insights in Cancer Biology and the Evolving Regulatory Landscape to Address Challenges and Guide Further Progress

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

FDA Approval Summary: Capecitabine Labeling Update under Project Renewal

Suchergebnisse filtern